

RESEARCH ARTICLE

The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retrospective Study

Emanuele D'Amico¹, Carmela Leone¹, Giusi Graziano², Maria Pia Amato³, Roberto Bergamaschi⁴, Paola Cavalla⁵, Gabriella Coniglio⁶, Giancarlo Di Battista⁷, Maria Teresa Ferrò⁸, Franco Granella⁹, Enrico Granieri¹⁰, Alessandra Lugaesi¹¹, Giacomo Lus¹², Enrico Millefiorini¹³, Carlo Pozzilli¹⁴, Giacchino Tedeschi¹⁵, Mario Zappia¹, Giancarlo Comi¹⁶, Maria Trojano¹⁷, Vito Lepore¹⁷, Francesco Patti^{1*}

1 MS center, Via S. Sofia, 78 95123, Catania, Italy, **2** Scientific Direction, National Cancer Institute "Giovanni Paolo II", Bari, Italy, **3** Department NEUROFARBA- University of Florence, Largo Brambilla 3, 50134, Florence, Italy, **4** CRISM, Istituto Neurologico Nazionale 'C. Mondino', Via Mondino 2, 27100, Pavia, Italy, **5** MS center, University of Turin, Via Cherasco, 15, Turin, Italy, **6** MS center, Hospital S. Carlo, Potenza, Italy, **7** MS center, Neurologia A.C.O. San Filippo Neri, Roma, Italy, **8** Hospital Maggiore, Crema, Italy, **9** Dipartimento di Neuroscienze, Via Volturmo 39, Parma, Italy, **10** MS center, University of Ferrara, Ferrara, Italy, **11** MS center, University of Chieti, Chieti, Italy, **12** Clinica Neurologica I, Seconda Università di Napoli Ed.10 Policlinico Federico II, Via Sergio Pansini 5, 80131, Napoli, Italy, **13** Policlinico Umberto I, Rome, Italy, **14** University La Sapienza, Rome, Italy, **15** II University of Naples, Napoli, Italy, **16** HSR, University San Raffaele, Milano, Italy, **17** University of Bari Aldo Moro, Bari, Italy

* patti@unicit.it

Abstract

Introduction

Immunosuppressive agents (ISA) have been used in multiple sclerosis (MS) for decades, frequently as off label licensed therapies. Given the new MS treatment landscape, what place do ISA have in combating MS?

Methods

We conducted a retrospective multicentre study to investigate the frequency of ISA prescription in 17 Italian MS centres, and to describe the clinical factors related to ISA use.

Results

Out of 6,447 MS patients, 2,034 (31.6%) were treated with ISA, with Azathioprine being the most frequently used ISA overall. MS patients treated with ISA alone were more frequently affected by the progressive course (both primary and secondary) of the disease (RRR 5.82, 95% CI 4.14–8.16, $p < 0.0001$), had higher EDSS (RRR 3.69, 95% CI 2.61–5.21, $p < 0.0001$), higher assignment age (RRR 1.04, 95% CI 1.03–1.06, $p < 0.0001$) than patients treated with only disease modifying drugs (DMDs).

Conclusions

Progressive course, higher EDSS, higher assignment age were the strongest predictors of ISA prescription and use in our population.



CrossMark
click for updates

OPEN ACCESS

Citation: D'Amico E, Leone C, Graziano G, Amato MP, Bergamaschi R, Cavalla P, et al. (2016) The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retrospective Study. PLoS ONE 11(6): e0157721. doi:10.1371/journal.pone.0157721

Editor: Hong-Liang Zhang, National Natural Science Foundation of China, CHINA

Received: October 14, 2015

Accepted: June 5, 2016

Published: June 27, 2016

Copyright: © 2016 D'Amico et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information file.

Funding: Merck supported iMED which is the software program used by for data acquisition at each collaborating centre and did not impact on the studies derived from data collected by this program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: Francesco Patti serves on scientific advisory boards for Teva, Biogen Idec,

Novartis, Bayer-Schering and receives speaker honoraria from Biogen Idec, Merck Serono, Novartis, Almirall, Bayer-Schering and Genzyme. Prof. Maria Pia Amato serves on scientific advisory boards for Biogen Idec, Merck Serono and receives speaker honoraria and research support from Biogen Idec, Merck Serono, Novartis, Almirall and Genzyme. Giancarlo Comi serves as an advisor or consultant or speaking activities for: Bayer HealthCare Pharmaceuticals; Merck Serono; Novartis Pharmaceuticals Corporation; sanofi-aventis; Schering-Plough Corporation; and Teva Pharmaceutical Industries Ltd. Maria Trojano received honoraria for consultancy or speaking from Biogen, Sanofi-Aventis, Merck Serono, Novartis, Genzyme, Teva, and Bayer-Schering and research grants from Merck Serono, Biogen, and Novartis. Gioacchino Tedeschi has received personal compensation for activities with Sanofi-Aventis Pharmaceuticals, Inc., Merck Serono, Bayer-Schering. Alessandra Lugaesi declared receipt of grants and contracts or honoraria and consultation fees by: Bayer Schering; Biogen Dompè; Merck Serono; Novartis; Serono Aventis. She is also member of a company advisory board, board of directors or other similar groups: Bayer Schering; Merck Serono; Biogen Idec. Carlo Pozzilli declared receipt of grants and contracts by: Merck Serono; Biogen Idec. He declared also receipt of honoraria or consultation fees by: Merck Serono; Biogen Idec, Novartis and Bayer. He is also member of a company advisory board, board of directors or other similar groups: Sanofi Aventis; Merck Serono; Biogen Idec. Mario Zappia serves on scientific advisory boards for Bayer-Schering and receives funding from Biogen Idec, Merck Serono, Novartis; speaking honoraria from Genzyme/Sanofi. The other authors report no disclosures relevant to the manuscript. Merck supported iMED which is the software program used by MSBASE for data acquisition at each collaborating centre and did not impact on the studies derived from data collected by this program. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all PLOS ONE policies on sharing data and materials.

Introduction

The proper choice of a treatment represents a major challenge in the management of the patients with MS [1].

From the beginning of its description, MS pathogenesis has been ascribed to a deviation of the immune system [2]. Immunosuppressive agents (ISA) are inhibitors of crucial components of the immune system and they were used early in MS treatment; but their use was frequently off-label [3]. Two classes of immunomodulatory agents (DMDs) have been approved for the treatment of relapsing–remitting MS (RR-MS), that is interferon- β (INFs), and glatiramer acetate (GA) [4]. DMDs are able to shift immune responses from a pro-inflammatory toward an anti-inflammatory status; thus they were considered first-line options in MS management to modify the disease course in MS [4]. Later, mitoxantrone (an ISA), has been approved for treatment of active forms of RRMS and secondary progressive MS (SPMS) [5]. Furthermore, in the last years a number of oral ISA became, or are going to be, available in the MS management as first-line option [6].

The treatment landscape of MS is dramatically changing and the role of ISA in MS therapy scenario need to be deeply reconsidered and rewritten. Data about the frequency of their use were collected in the past, involving different countries worldwide; and the frequency of ISA prescription was found to be around 10% [7–8]. There were strong differences in frequency of ISA treatments per country [7–8]. To date we were unable to identify any large-scale clinical trials that characterize ISA prescription use in MS patients. Nonetheless, ISA continue to be used in MS patients, given that some patients are refractory to more conventional therapies or experienced contraindications to the use of more modern MS treatments such as with fingolimod or natalizumab. We designed and performed this study in Italy (involving the two principal regional areas) looking first at the frequency of ISA use. Moreover, we described the clinical features of MS patients who were ISA exposed to start questioning how and when it is possible thinking about ISA use in the clinical practice.

Our work could help the clinical neurologists to gain more insight in ISA prescription and use in MS therapy scenario and to consider how the use of ISA must be critically re-evaluated in the light of the recent changes in MS treatment landscape.

Methods

A retrospective analysis of prospectively collected data was performed. The settings were referral subspecialty MS clinics in Italy. Twenty-five Italian MS centres (members of Italian iMED-Web registry) were asked to participate in survey. Seventeen MS centres in the two different Italy's regional area (eight in the North-Centre area, eight in the South-Sicily Island area) confirmed the participation in the study.

Clinical and demographical data of MS patients were recorded at each of the collaborating centers using the offline medical record iMED (Serono International SA, Geneva, Switzerland) and then uploaded to the Italian iMedWeb registry. The use of iMED as a research platform was approved by the local human research ethics committee at all participating centers. Quality assurance of clinical data was maintained by inbuilt data quality checking in the iMED local record system. To ensure consistency of Expanded Disability Status Score (EDSS) evaluations all neurologists completed the Neurostatus certification (<http://www.neurostatus.net>) or provided evidence of prior completion of this certification.

We searched through iMED software querying ISA and DMDs prescription. We identified two main groups of treated patients with MS: a group treated with ISA and a group treated with DMDs. The inclusion criteria were: i) diagnosis of MS according to Poser or McDonald criteria [9–10]; ii) disease duration of at least three years (evaluated as difference in time: last visit-onset disease); iii) at least three neurological evaluations performed by senior, trained

neurologists in the MS diagnosis and management. We did not take in account patients being enrolled in experimental phase III studies. To avoid clinical misclassification we merged the secondary progressive and primary progressive patients below the umbrella definition of progressive forms, independently on their “activity status” [11]. ISA group included the patients treated at least one time with one or more of four drugs: azathioprine (AZA), cyclophosphamide (Cyc), methotrexate (MT) and mitoxantrone (MTX).

We divided the ISA group in three different subgroups: patients treated with ISA alone (arbitrarily defined as “*pure ISA*” therapy regimen), patients treated with ISA as first-therapy and then with DMDs (defined as “*induction*” therapy regimen) and patients treated with DMDs as first-therapy and then ISA (defined as “*escalation*” therapy regimen).

The fourth subgroup included DMDs patients, that is all MS patients treated with one or more of the different INFs formulations [Avonex® (Interferon beta-1a intramuscular once a week; Betaferon® (interferon beta-1b subcutaneous every second day); Extavia® (Interferon beta-1b subcutaneous every second day) Rebif® (Interferon beta-1a, at dosage of 22 or 44 micrograms subcutaneous three times per week and Copaxone® (Glatiramer Acetate subcutaneous every day)].

AZA was prescribed at variable doses ranging from 50 to 200 mg daily orally administered. Cyc was prescribed intravenously every month, 750–2000 mg per month with a cumulative dose of 4.800–30.000 mg per patient. MT was prescribed at doses of 7.5–15 mg weekly in 1–2 different oral administrations. MTX was prescribed intravenously at doses of 10–20 mg monthly for a cumulative dose of 60–200 mg.

The date of the enrollment visit was the date of the first therapy prescription and administration (ISA or DMDs). The EDSS [12] was recorded at baseline and at least every 3 months subsequently to determine the disability’s accrual.

Ethics: the study received the approval of the coordinating centre Ethical Committee (at Catania University). The participating centres informed their ethical committee, before making available informatics records of their patients at each centre. All of the recruited patients had signed an informed consent.

Statistical analysis

Baseline characteristics of whole population were reported as frequencies and percentages for categorical variables and mean \pm standard deviation (sd) for continuous variables. Disease duration was also reported as categorical variables. In particular, it was dichotomized according to clinical relevant cut off [13–15].

Patients were divided into four groups based on assigned therapy as previously indicated. Comparisons among multiple groups and associations with clinical parameters were performed with univariate multinomial logistic regression models. Multivariable analyses, with stepwise selection, were also conducted to investigate the effect of some confounding factors on the outcome of interest. Evaluated variables were those resulting significant at univariate analyses. The results were presented as relative risk ratios (RRR) with corresponding 95% confidence intervals and p-values. In a second step, the attention was focused on two main subgroups (all ISA vs DMDs). In this case simple and multiple logistic models were considered. Cochran-Armitage test was used to test for trend among proportions. The statistical significance was achieved at a p-value < 0.05. All the analyses were performed using the Statistical Analysis System (SAS) Package, Release 9.2 (SAS Institute, Cary, NC, USA).

Results


From a total sample of 11,335 MS patients, 6,447 (83%) patients were considered eligible for frequency analyses [S1 Table]. A number of 4,413 (68.4%) were treated with DMDs (INFs or

GA) and 2,034 (31.6%) with ISA. Out of 2,034, 580 were classified as pure ISA, 501 were in induction scheme and 953 were in escalation scheme (Fig 1). Out of 2,034 ISA treated patients, AZA was the most frequently used in monotherapy (41.4%), followed by MTX (24.4%), then Cyc (7.9%) and MT (4.4%). The 21.9% of the whole group assigned to ISA treatment had used more than one single ISA drug.

A total of 4,624 patients were affected by RRMS and 1,006 suffered from progressive forms of MS (PFMS). The remaining 817 patients with MS were not yet clinical classified, because they had no the international used criteria [11–16] to be assigned to one of the two MS groups. EDSS evaluations were disposable in 4,202 patients and about 78% of patients had and EDSS value lower than 4.0. See Table 1.

Table 2 shows the results of univariate multinomial logistic regression analyses. Regarding the age at MS onset, pure ISA subgroup had an older age, than DMDs and ISA subgroup ($p < 0.0001$). Moreover, pure ISA group had significant higher assignment age than DMDs ($p < 0.0001$). Regarding clinical characteristics, we found that pure ISA subgroup had longer disease duration (that is equal/more than five years) than DMDs. All ISA subgroups (pure, induction, escalation) experienced more frequently progressive course of the disease than DMDs ($p < 0.0001$ for all). All ISA subgroups showed higher level of disability (EDSS value equal or higher of 4.0) ($p < 0.0001$ for all) than DMDs group.

Flow-chart enrollment of the study



ISA, Immunosuppressant agents; DMDs, disease modifying drugs; MS, multiple sclerosis

Fig 1. Shows the distribution of ISA subgroups in our cohort.

doi:10.1371/journal.pone.0157721.g001

Table 1. Patients' characteristics at baseline.

Variable	Number (%) or mean±sd
Number	6,447
Age at onset	28.51±9.34
Assignment age	36±10.44
Disease duration	
<5	3,328 (82.13)
≥5	3,119 (48.38)
Disease course	
RR	4,624 (82.13)
PP	1,006 (17.87)
EDSS	
<4	3,291(78.32)
≥4	911(21.68)
SEX	
M	2,097 (32.53)
F	4,350 (67.47)
Geographical areas	
Centre-North	2,670 (41.41)
South-Island	3,777(58.59)

doi:10.1371/journal.pone.0157721.t001

The multivariable multinomial logistic analyses confirmed the univariate results (Table 3). Pure ISA subgroup had an older assignment age, more frequently PFMS and higher EDSS value than DMDs. Also induction and escalation ISA subgroups showed more frequently

Table 2. Univariate multinomial logistic regression analyses.

Effect	n	Therapy (ref = DMDs)	RRR(95% CI)	p-value
Age at onset	580	Pure ISA	1.05(1.04–1.06)	<0.0001
	501	Induction	1.00(0.99–1.01)	0,339
	953	Escalation	0.99(0.99–1.01)	0,87
Assignment age	580	Pure ISA	1.08(1.07–1.09)	<0.0001
	501	Induction	1.01(0.99–1.02)	0,108
	953	Escalation	1(0.99–1.01)	0,972
Disease duration (= >5 vs <5)	580	Pure ISA	2.59(2.15–3.12)	<0.0001
	501	Induction	1.05(0.87–1.26)	0,638
	953	Escalation	1.07(0.93–1.23)	0,358
Disease course (PP vs RR)	518	Pure ISA	15.87(12.89–19.54)	<0.0001
	435	Induction	5.22(4.16–6.55)	<0.0001
	759	Escalation	3.54(2.91–4.30)	<0.0001
EDSS (= >4 vs <4)	336	Pure ISA	14.28(11.07–18.43)	<0.0001
	195	Induction	4.81(3.56–6.48)	<0.0001
	515	Escalation	2.10(1.68–2.62)	<0.0001
SEX (M vs F)	580	Pure ISA	1.37(1.15–1.64)	0,0006
	501	Induction	1.29(1.06–1.56)	0,009
	953	Escalation	1.27(1.09–1.47)	0,002
Geographical areas (South-Islands vs Centre-North)	580	Pure ISA	1.68(1.39–2.02)	<0.0001
	501	Induction	1.05(0.87–1.26)	0,643
	953	Escalation	1.33(1.15–1.54)	0,0001

doi:10.1371/journal.pone.0157721.t002

Table 3. Multivariable multinomial logistic regression analyses.

Effect	Mean± SD or n (%)	Therapy (ref = DMDs)	RRR(95% CI)	p-value
Assignment age	44.14±12.02	<i>Pure ISA</i>	1.04(1.03–1.06)	<0.0001
	35.9±10.7	<i>Induction</i>	0.98(0.96–0.99)	0,006
	35.12±9.48	<i>Escalation</i>	0.99(0.98–1.00)	0,057
Disease course (PP vs RR)	315(60.81)	<i>Pure ISA</i>	5.82(4.14–8.16)	<0.0001
	147(33.79)	<i>Induction</i>	3.24(2.07–5.06)	<0.0001
	195(25.69)	<i>Escalation</i>	2.91(2.09–4.05)	<0.0001
EDSS (= >4 vs <4)	237(70.54)	<i>Pure ISA</i>	3.69(2.61–5.21)	<0.0001
	87(44.62)	<i>Induction</i>	3.33(2.21–5.02)	<0.0001
	134(26.02)	<i>Escalation</i>	1.57(1.16–2.12)	0,003
Geographical areas (South-Islands vs Centre-North)	397(68.45)	<i>Pure ISA</i>	1.45(1.06–1.97)	0,018
	288(57.49)	<i>Induction</i>	1.29(0.90–1.84)	0,168
	603(63.27)	<i>Escalation</i>	1.36(1.08–1.72)	0,009

doi:10.1371/journal.pone.0157721.t003

PFMS and higher EDSS value than DMDs. The findings were all statistically significant. We also found that in South-Island area there was higher frequency of pure and escalation ISA than DMDs compared with the Centre-North area ($p < 0.05$ and < 0.01 , respectively).

Paying attention to the relation between the assigned therapy and the disease course it could be noticed that there was a decreasing percentage of progressive forms from pure ISA subgroup (the highest) to DMDs group (the lowest) (Fig 2). The trend showed in Fig 2 was confirmed by the Cochran-Armitage test ($p < 0.0001$).

At the univariate logistic regression analyses (Table 4) all patients treated with ISA (pure, induction, escalation subgroups) were older at onset and at therapy assignment than DMDs group ($p < 0.0001$). They also experienced longer disease duration ($p < 0.0001$), PFMS ($p < 0.0001$) and higher EDSS ($p < 0.0001$). Furthermore these patients were more frequently men ($p < 0.0001$) and settled in the South-Island area ($p < 0.0001$). The multiple logistic regression confirmed only disease course, EDSS and geographical areas as independent predictors of ISA therapy (Table 5).

Discussion

About 30% of our MS patients had received at least one ISA prescription. MS patients who were older at age of therapy assignment and with higher disability (in terms of EDSS and PFMS course), have more frequently used ISA as pure ISA regimen. Moreover, pure ISA were more frequently prescribed in the South-Island area of our country, Italy. Previously, a worldwide survey about ISA prescription (including AZA, Cyc, MT, MTX) in 191 MS centres showed a mean percentage of ISA use about 10% [7]. Regarding Europe, France had the highest percentage (32.5%), and Italy had 12.7% of ISA use [7].

This study has potential limits, the first one is the retrospective design, although data were prospectively collected in each centre on patients who were regularly followed up. It also has the limit to miss data regarding patients without inclusion criteria (almost 3 years disease duration), or patients lost at follow-up (mainly because of moving to other centres). Moreover, the missing data in EDSS field, which did not invalidate the results.

In the last years, MS therapeutic armamentarium has dramatically grown up [17]. The introduction of new drugs with immunosuppressant profile has led the MS clinician to take in account an earlier and more aggressive approach in the MS treatment [17]. Nevertheless, the paucity of long term safety data, may have limited their use in the clinical practice. So, ISA may represent a useful therapeutic option to satisfy a new therapeutic approach aimed at a more aggressive and even earlier treatment with a well-known profile of toxicity.

ISA and DMDs' use among the different MS phenotypes (relapsing remitting and progressive forms)




Fig 2. Shows the relation between the assigned therapy and the disease course in alla ISA subgroups and DMDs group.

doi:10.1371/journal.pone.0157721.g002

Table 4. Univariate logistic regression analyses performed on all ISA patients vs others.

Effect	mean±sd or n (%)	OR (95% CI)	p-value
Age at onset	29.46±10	1.016(1.010–1.022)	<0.0001
Assignment age	37.88±9.92	1.025(1.02–1.03)	<0.0001
Disease duration (= >5 vs <5)	1089(53.54)	1.35(1.22–1.50)	<0.0001
Disease course (PP vs RR)	657(38.38)	6.37(5.50–7.38)	<0.0001
EDSS (= >4 vs <4)	458(43.79)	4.65(3.97–5.44)	<0.0001
SEX (M vs F)	743(36.53)	1.30(1.16–1.45)	<0.0001
Geographical areas (South-Islands vs Centre-North)	1288(63.32)	1.34(1.20–1.49)	<0.0001

doi:10.1371/journal.pone.0157721.t004

Table 5. Multivariable logistic regression analyses performed on all ISA patients vs others.

Effect	meant±sd or n (%)	OR(95% CI)	p-value
Disease course	657 (38.38)	4.03(3.19–5.09)	<0.0001
(PP vs RR)			
EDSS	458 (43.79)	2.44(1.97–3.01)	<0.0001
(= >4 vs <4)			
Geographical areas	1288(63.32)	1.37(1.14–1.64)	0,0007
(South-Islands vs Centre-North)			

doi:10.1371/journal.pone.0157721.t005

In a recent non-inferiority trial 150 patients with RRMS were randomized to receive AZA 3 mg/kg daily (n = 77) or INF beta-1a 22 or 44 µg (n = 69) or INF beta-1b (n = 4) for two years. The intent-to-treat analysis was done on 68 and 63 patients, respectively. Annualized relapse rates were not significantly different between the AZA and INF-beta groups in the first (0.37 vs 0.47; p<0.05 and second (0.18 vs 0.29; p<0.05) years and, when combined for the two years, the annualized relapse rate was lower in the AZA group (0.26 vs 0.39; p<0.05 p = 0.07) [18]. In the AZA group there were more treatment discontinuations than in the INFs group because of adverse events [18]. These interesting data showed that AZA may be as effective as INFβ in RRMS as first-line therapy and shed new light on the possibility that MS physicians might use ISA as a suitable first line-drug to be prescribed. Obviously, such a strategy requires closer clinical monitoring during the first years, in particular to titrate the dose according to the lymphocyte count, and in general to manage all alerts reflecting a possible individual susceptibility. On the other hand, for some patients, ISA could provide a higher quality of life without the flu-like symptoms of INF or because of a less invasive route of administration, and with a known side effect profile, which could be easily monitored.

Progressive course of MS (both primary and secondary) and higher level of disability were correlated to overall ISA prescription in our study. These data are in line with previous reports about a higher ISA use in PFMS, that is in more impaired patients, and moreover, a preferred use as second-line therapy [8]. However, in our sample, the 39.2% of patients who had used ISA alone (pure ISA subgroup) did not have PFMS; and the percentage of patients with RRMS who had used ISA in escalation or induction was around 70%.

Two different therapeutic approaches are actually used in MS: escalation and induction therapy. Escalation therapy consists of starting, in the early phases of the disease, with first line DMDs (INFs, GA, teriflunomide, dimethyl fumarate) and if DMDs are ineffective or partially effective, a switch to second line drugs (MTX, natalizumab, fingolimod and other off-label used ISA as AZA, Cyc, MTX) and, in case of more failures, a third line options, such as alemtuzumab or autologous hematopoietic transplant could be considered[17]. Induction therapy consists of the early use of more aggressive therapy (such as ISA) followed by long-term maintenance treatment, generally with DMDs [19]. The use of natalizumab and fingolimod as first line drugs is indicated for aggressive forms of RRMS [17]. Both escalating and induction strategies can be successfully applied on the basis of clinical and radiological data; apart from clinically aggressive RRMS, for which induction treatment could be regarded as the first line of treatment. The use of more aggressive drugs in MS will make it particularly important to have long term safety data.

Both MTX and Cyc have the limit of cumulative doses [20–23]. Fewer concerns are raised by AZA; it was reported that long periods of treatment with this drug could expose patients to the risk of malignancies [24].

In the last decades, the economic burden of the disease has also received increasing attention, especially when considering efforts aimed to control public expense along with the decline

of available resources for the healthcare services in Western countries [23]. Costs of MS are highly due to the chronic nature of the disease, the need for hospitalization during phases of severe relapses and to the gradual increase in disability, which may necessitate assistance with daily life activities.

In Italy, MS is the second CNS disorder for cost per patient, with an estimated cost of around €25,000 per MS patient/year; the costs of DMDs were significantly lower for patients with EDSS scores higher than 4.0 [25]. All of these reasons underline as the therapeutic decisions of the MS physician have to take into account the related economic weight. Probably, among the reasons of the prominent use of ISA in South-Island area of Italy, there was a different economic organization of the local healthcare system [25].

Several new drugs have recently demonstrated their efficacy in RRMS in randomized controlled phase III trials, and have been recently approved in some countries or their approval can be expected in the near future [26]. The future challenge will be to choose the most efficacious and safe drug for the individual patient. Biomarkers that help to predict these issues in the individual are mandatory [27]. The course of MS varies between individuals and intra-individual during the course of the disease: some patients accumulate minimal disability over their lives, whereas others experience a rapidly disabling disease course. This latter subset of patients show a rampant progression of disability over a short time period, and they are referred to have an 'aggressive' MS. Treatment of patients with aggressive MS is challenging, and optimal strategies have yet to be defined.

Given potentially severe side-effects of newer agents for the treatment of patients with MS, including monoclonal antibodies that possess immunosuppressive properties, it is likely that the established immunosuppressant approach will not be replaced in the therapy of MS in the near future. A selected group of highly active MS patients may benefit from a "hit hard and early" approach, driven by the essential aim to suppress the inflammatory cascade which plays a crucial role in the early stage of the disease. It is clear that more investigations are needed to clarify the optional therapeutic strategies for MS treatment.

Names of drugs: Avonex® (Interferon beta-1a intramuscular once a week); Betaferon® (Interferon beta-1b subcutaneous every second day); Extavia® (Interferon beta-1b subcutaneous every second day); Rebif® (Interferon beta-1a, at dosage of 22 or 44 micrograms subcutaneous three times per week, Copaxone® (Glatiramer Acetate subcutaneous every day); Azathioprine; Metotrexate; Mitoxantrone; Cyclophosphamide; Tysabri® (natalizumab); Gylenia® (Fingolimod).

Supporting Information

S1 Table. This excel file shows the entire database of our multi center study. (XLS)

Author Contributions

Conceived and designed the experiments: ED FP. Performed the experiments: FP ED CL GG MPA RB PC G. Coniglio GDB MTF FG EG AL GL EM CP GT VL MZ G. Comi MT. Analyzed the data: VL GG. Wrote the paper: FP ED CL GG MPA RB PC G. Coniglio GDB MTF FG EG AL GL EM CP GT VL MZ G. Comi MT. Accepted the final version of the work: FP.

References

1. Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. *Mayo Clin Proc.* 2014 Feb; 89(2):225–40. doi: [10.1016/j.mayocp.2013.11.002](https://doi.org/10.1016/j.mayocp.2013.11.002) PMID: [24485135](https://pubmed.ncbi.nlm.nih.gov/24485135/)

2. Hemmer B, Kerschensteiner M, Korn T. Role of the innate and adaptive immune responses in the course of multiple sclerosis. *Lancet Neurol*. 2015 Apr; 14(4):406–19. doi: [10.1016/S1474-4422\(14\)70305-9](https://doi.org/10.1016/S1474-4422(14)70305-9) PMID: [25792099](https://pubmed.ncbi.nlm.nih.gov/25792099/)
3. Stankiewicz JM, Kolb H, Karni A, Weiner HL. Role of immunosuppressive therapy for the treatment of multiple sclerosis. *Neurotherapeutics*. 2013 Jan; 10(1):77–88. doi: [10.1007/s13311-012-0172-3](https://doi.org/10.1007/s13311-012-0172-3) PMID: [23271506](https://pubmed.ncbi.nlm.nih.gov/23271506/)
4. English C, Aloï JJ. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis. *Clin Ther*. 2015 Apr 1; 37(4):691–715. doi: [10.1016/j.clinthera.2015.03.001](https://doi.org/10.1016/j.clinthera.2015.03.001) PMID: [25846320](https://pubmed.ncbi.nlm.nih.gov/25846320/)
5. Martinelli Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. *Cochrane Database Syst Rev*. 2013 May 31
6. Safavi M, Nikfar S, Abdollahi M. A systematic review of drugs in late-stage development for the treatment of multiple sclerosis: a focus on oralsynthetic drugs. *Inflamm Allergy Drug Targets*. 2015 May 28.
7. Hommes OR and Weiner HL. Results of an international questionnaire on immunosuppressive treatment of multiple sclerosis *Mult Scler* 2002 8, 139:141
8. Hommes OR and Weiner HL. Clinical practice of immunosuppressive treatment in multiple sclerosis: results of a second international questionnaire *J Neurol Sci* 2004 223(1) 65–7. PMID: [15261563](https://pubmed.ncbi.nlm.nih.gov/15261563/)
9. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. "New diagnostic criteria for multiple sclerosis: Guidelines for research protocols". *Annals of Neurology* 1983 13 (3): 227–31. PMID: [6847134](https://pubmed.ncbi.nlm.nih.gov/6847134/)
10. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. "Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria. *Ann. Neurol*. 2005 58 (6): 840–6 PMID: [16283615](https://pubmed.ncbi.nlm.nih.gov/16283615/)
11. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. *Neurology*. 2014 Jul 15; 83(3):278–86. doi: [10.1212/WNL.0000000000000560](https://doi.org/10.1212/WNL.0000000000000560) PMID: [24871874](https://pubmed.ncbi.nlm.nih.gov/24871874/)
12. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). *Neurology* 1983 33 (11): 1444–52. PMID: [6685237](https://pubmed.ncbi.nlm.nih.gov/6685237/)
13. Scalfari A, Neuhaus A, Daumer M, Ebers GC, Muraro PA. Age and disability accumulation in multiple sclerosis. *Neurology*. 2011 Sep 27; 77(13):1246–52. doi: [10.1212/WNL.0b013e318230a17d](https://doi.org/10.1212/WNL.0b013e318230a17d) PMID: [21917763](https://pubmed.ncbi.nlm.nih.gov/21917763/)
14. Leray E, Yaouanq J, Le Page E, Coustans M, Laplaud D, Oger, et al. Evidence for a two-stage disability progression in multiple sclerosis. *Brain*. 2010 Jul; 133(Pt 7):1900–13. doi: [10.1093/brain/awq076](https://doi.org/10.1093/brain/awq076) PMID: [20423930](https://pubmed.ncbi.nlm.nih.gov/20423930/)
15. Simone IL, Carrara D, Tortorella C, Liguori M, Lepore V, et al. Course and prognosis in early-onset MS: comparison with adult-onset forms. *Neurology*. 2002 Dec 24; 59(12):1922–8. PMID: [12499484](https://pubmed.ncbi.nlm.nih.gov/12499484/)
16. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. *Neurology* 1996; 46:907–911 PMID: [8780061](https://pubmed.ncbi.nlm.nih.gov/8780061/)
17. Torkildsen Ø, Myhr KM, Bø L. Disease-modifying treatments for multiple sclerosis—a review of approved medications. *Eur J Neurol*. 2016 Jan; 23 Suppl 1:18–27. doi: [10.1111/ene.12883](https://doi.org/10.1111/ene.12883) PMID: [26563094](https://pubmed.ncbi.nlm.nih.gov/26563094/)
18. Massacesi L, Tramacere I, Amoroso S, Battaglia MA, Benedetti MD, Filippini G, et al. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial. *PLoS One*. 2014 Nov 17; 9(11):e113371. doi: [10.1371/journal.pone.0113371](https://doi.org/10.1371/journal.pone.0113371) PMID: [25402490](https://pubmed.ncbi.nlm.nih.gov/25402490/)
19. Edan G, Le Page E. Induction therapy for patients with multiple sclerosis: why? When? How? *CNS Drugs*. 2013 Jun; 27(6):403–9. doi: [10.1007/s40263-013-0065-y](https://doi.org/10.1007/s40263-013-0065-y) PMID: [23657788](https://pubmed.ncbi.nlm.nih.gov/23657788/)
20. Kingwell E, Koch M, Leung B, Isserow S, Geddes J, Rieckmann P, et al. Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. *Neurology*. 2010 Jun 1; 74(22):1822–6. doi: [10.1212/WNL.0b013e3181e0f7e6](https://doi.org/10.1212/WNL.0b013e3181e0f7e6) PMID: [20427751](https://pubmed.ncbi.nlm.nih.gov/20427751/)
21. Scott LJ, Figgitt DP Mitoxantrone: a review of its use in multiple sclerosis. *CNS Drugs*. 2004; 18 (6):379–96. PMID: [15089110](https://pubmed.ncbi.nlm.nih.gov/15089110/)
22. Perini P, Calabrese M, Rinaldi L, Gallo P. The safety profile of cyclophosphamide in multiple sclerosis therapy. *Expert Opin Drug Saf*. 2007 Mar; 6(2):183–90. PMID: [17367264](https://pubmed.ncbi.nlm.nih.gov/17367264/)
23. Patti F, Lo Fermo S. Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis. *Autoimmune Dis*. 2011 Mar 15; 2011:961702. doi: [10.4061/2011/961702](https://doi.org/10.4061/2011/961702) PMID: [21547093](https://pubmed.ncbi.nlm.nih.gov/21547093/)
24. La Mantia L, Mascoli N, Milanese C. Azathioprine. Safety profile in multiple sclerosis patients. *Neurol Sci*. 2007 Dec; 28(6):299–303. doi: [10.1007/s10072-007-0842-9](https://doi.org/10.1007/s10072-007-0842-9) PMID: [18175075](https://pubmed.ncbi.nlm.nih.gov/18175075/)
25. Patti F, Amato MP, Trojano M, Solaro C, Pappalardo A, Zipoli V, et al. Multiple sclerosis in Italy: cost-of-illness study. *Neurol Sci*. 2011 Oct; 32(5):787–94. doi: [10.1007/s10072-011-0499-2](https://doi.org/10.1007/s10072-011-0499-2) PMID: [21409509](https://pubmed.ncbi.nlm.nih.gov/21409509/)

26. Kamm CP, Uitdehaag BM, Polman CH. Multiple sclerosis: current knowledge and future outlook. *Eur Neurol*. 2014; 72(3–4):132–41. doi: [10.1159/000360528](https://doi.org/10.1159/000360528) Epub 2014 Jul 30. PMID: [25095894](https://pubmed.ncbi.nlm.nih.gov/25095894/)
27. Katsavos S, Anagnostouli M. Biomarkers in multiple sclerosis: an up-to-date overview. *Mult Scler Int* 2013; 2013:340508 doi: [10.1155/2013/340508](https://doi.org/10.1155/2013/340508) PMID: [23401777](https://pubmed.ncbi.nlm.nih.gov/23401777/)